Psilocybin-occasioned Mystical Experiences in the Treatment of Tobacco Addiction

Overview

Journal Curr Drug Abuse Rev

Publisher Bentham Science Publishers

Specialty Psychiatry

Date 2015 Jan 8

PMID 25563443

Citations 159

Authors

Albert Garcia-Romeu

Roland R Griffiths

Matthew W Johnson

Affiliations

Soon will be listed here.

Abstract

Psilocybin-occasioned mystical experiences have been linked to persisting effects in healthy volunteers including positive changes in behavior, attitudes, and values, and increases in the personality domain of openness. In an open-label pilot-study of psilocybin-facilitated smoking addiction treatment, 15 smokers received 2 or 3 doses of psilocybin in the context of cognitive behavioral therapy (CBT) for smoking cessation. Twelve of 15 participants (80%) demonstrated biologically verified smoking abstinence at 6-month follow-up. Participants who were abstinent at 6 months (n=12) were compared to participants still smoking at 6 months (n=3) on measures of subjective effects of psilocybin. Abstainers scored significantly higher on a measure of psilocybin-occasioned mystical experience. No significant differences in general intensity of drug effects were found between groups, suggesting that mystical-type subjective effects, rather than overall intensity of drug effects, were responsible for smoking cessation. Nine of 15 participants (60%) met criteria for "complete" mystical experience. Smoking cessation outcomes were significantly correlated with measures of mystical experience on session days, as well as retrospective ratings of personal meaning and spiritual significance of psilocybin sessions. These results suggest a mediating role of mystical experience in psychedelic-facilitated addiction treatment.

Citing Articles

The Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item.

Strickland J, Garcia-Romeu A, Johnson M Psychedelic Med (New Rochelle). 2025; 2(1):33-43.

PMID: 40051759 PMC: 11658653. DOI: 10.1089/psymed.2023.0046.

Acute Subjective Experiences of Intravenous Ketamine Therapy Among Medically Hospitalized Patients with Alcohol Use Disorder.

Terasaki D Psychedelic Med (New Rochelle). 2025; 2(2):116-126.

PMID: 40051584 PMC: 11658664. DOI: 10.1089/psymed.2023.0066.

Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings.

Nicholas C, Horton D, Malicki J, Baltes A, Hutson P, Brown R Psychedelic Med (New Rochelle). 2025; 1(4):253-261.

PMID: 40046866 PMC: 11661506. DOI: 10.1089/psymed.2023.0012.

Learned Helplessness As a Potential Transdiagnostic Therapeutic Mechanism of Classic Psychedelics.

Tiwari P, Berghella A, Sayali C, Doss M, Barrett F, Yaden D Psychedelic Med (New Rochelle). 2025; 1(2):74-86.

PMID: 40046726 PMC: 11658661. DOI: 10.1089/psymed.2023.0010.

Medical Students' Attitudes and Beliefs Toward Psilocybin: Does Terminology and Personal Experience with Psychedelics Matter?.

Pagan A, Lex C, Soares J, Meyer T Psychedelic Med (New Rochelle). 2025; 1(3):130-138.

PMID: 40046569 PMC: 11661472. DOI: 10.1089/psymed.2023.0022.

References

Shin L, Rauch S, Pitman R . Amygdala, medial prefrontal cortex, and hippocampal function in PTSD. Ann N Y Acad Sci. 2006; 1071:67-79. DOI: 10.1196/annals.1364.007. View

Strassman R, Qualls C, Uhlenhuth E, Kellner R . Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry. 1994; 51(2):98-108. DOI: 10.1001/archpsyc.1994.03950020022002. View

MacLean K, Johnson M, Griffiths R . Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011; 25(11):1453-61. PMC: 3537171. DOI: 10.1177/0269881111420188. View

Welch B . The generalisation of student's problems when several different population variances are involved. Biometrika. 2010; 34(1-2):28-35. DOI: 10.1093/biomet/34.1-2.28. View

Vollenweider F, Kometer M . The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010; 11(9):642-51. DOI: 10.1038/nrn2884. View

Sarett M, Cheek F, Osmond H . Reports of wives of alcoholics of effects of LSD-25 treatment of their husbands. Arch Gen Psychiatry. 1966; 14(2):171-8. DOI: 10.1001/archpsyc.1966.01730080059009. View

Hopper J, Frewen P, van der Kolk B, Lanius R . Neural correlates of reexperiencing, avoidance, and dissociation in PTSD: symptom dimensions and emotion dysregulation in responses to script-driven trauma imagery. J Trauma Stress. 2007; 20(5):713-25. DOI: 10.1002/jts.20284. View

Pahnke W, Kurland A, Unger S, Savage C, Grof S . The experimental use of psychedelic (LSD) psychotherapy. JAMA. 1970; 212(11):1856-63. View

Brewer J, Mallik S, Babuscio T, Nich C, Johnson H, DeLeone C . Mindfulness training for smoking cessation: results from a randomized controlled trial. Drug Alcohol Depend. 2011; 119(1-2):72-80. PMC: 3191261. DOI: 10.1016/j.drugalcdep.2011.05.027. View

10.

Kraehenmann R, Preller K, Scheidegger M, Pokorny T, Bosch O, Seifritz E . Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. Biol Psychiatry. 2014; 78(8):572-81. DOI: 10.1016/j.biopsych.2014.04.010. View

11.

Bramer S, Kallungal B . Clinical considerations in study designs that use cotinine as a biomarker. Biomarkers. 2003; 8(3-4):187-203. DOI: 10.1080/13547500310012545. View

12.

Carhart-Harris R, Erritzoe D, Williams T, Stone J, Reed L, Colasanti A . Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A. 2012; 109(6):2138-43. PMC: 3277566. DOI: 10.1073/pnas.1119598109. View

13.

Johnson M, Garcia-Romeu A, Cosimano M, Griffiths R . Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014; 28(11):983-92. PMC: 4286320. DOI: 10.1177/0269881114548296. View

14.

Pahnke W . Psychedelic drugs and mystical experience. Int Psychiatry Clin. 1969; 5(4):149-62. View

15.

Tiffany S, Drobes D . The development and initial validation of a questionnaire on smoking urges. Br J Addict. 1991; 86(11):1467-76. DOI: 10.1111/j.1360-0443.1991.tb01732.x. View

16.

Kuhn S, Gallinat J . Gray matter correlates of posttraumatic stress disorder: a quantitative meta-analysis. Biol Psychiatry. 2012; 73(1):70-4. DOI: 10.1016/j.biopsych.2012.06.029. View

17.

Hollister L, Shelton J, Krieger G . A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetmine in alcoholics. Am J Psychiatry. 1969; 125(10):1352-7. DOI: 10.1176/ajp.125.10.1352. View

18.

Ludwig A, Levine J, Stark L, Lazar R . A clinical study of LSD treatment in alcoholism. Am J Psychiatry. 1969; 126(1):59-69. DOI: 10.1176/ajp.126.1.59. View

19.

Mottillo S, Filion K, Belisle P, Joseph L, Gervais A, OLoughlin J . Behavioural interventions for smoking cessation: a meta-analysis of randomized controlled trials. Eur Heart J. 2008; 30(6):718-30. DOI: 10.1093/eurheartj/ehn552. View

20.

Elzinga B, Bremner J . Are the neural substrates of memory the final common pathway in posttraumatic stress disorder (PTSD)?. J Affect Disord. 2002; 70(1):1-17. PMC: 5580811. DOI: 10.1016/s0165-0327(01)00351-2. View